Abstract / Summary
Purpose: Although radiation therapy response involves biological processes shared across cancers, most biomarker studies rely on small, disease-specific sample sizes that limit the reliability of prognostic models. This study evaluated whether pan-cancer data can increase the information available for estimating genomic associations with progression after radiation therapy, based on Molecular Signatures Database hallmark gene sets applied to The Cancer Genome Atlas patients. Methods and Materials: Cross-cancer predictive potential was evaluated in cancer types with at least 100 patients who received radiation therapy and had information on gene expression, progression, age, stage, and gender: breast invasive carcinoma (n = 553), cervical squamous cell carcinoma (n = 183), head-neck squamous cell carcinoma (n = 320), low-grade glioma (n = 316), lung adenocarcinoma (n = 104), skin cutaneous melanoma (n = 125), thyroid cancer (n = 326), and uterine corpus endometrial carcinoma ( n = 257 ). Gene set expression scores were calculated at the single-sample level. For each evaluation cancer type, scores from all other types were used to fit pan-cancer Cox proportional hazards models. Linear predictions from these models were evaluated in per-cancer prognostication via Kaplan–Meier curves, Cox proportional hazards estimates, including adjustment for age, stage, and gender, and optimism-corrected C-statistic and Nagelkerke pseudo-R 2 . Results: In Kaplan–Meier analysis, pan-cancer scores predicted progression in all cancer types, with varying statistical significance. Univariable Cox proportional hazards models also demonstrated consistent association with progression, again with varying significance. Associations persisted when adjusted for clinical variables, and model performance metrics indicated the potential to improve per-cancer prognostication. Associations were particularly strong for breast invasive carcinoma, cervical squamous cell carcinoma, head-neck squamous cell carcinoma, low-grade glioma, and lung adenocarcinoma, with statistically insignificant results for skin cutaneous melanoma, thyroid cancer, and uterine corpus endometrial carcinoma. Conclusions: Pan-cancer gene expression data can predict per-cancer progression after radiation therapy, with variable strength across cancer types. These findings support the use of cross-cancer genomic information to address sample size limitations that affect radiation therapy biomarker development.